The corona virus has caused businesses throughout the world to find new ways to deliver products and services to consumers. The healthcare industry is no exception. Though “telehealth” has been an emerging technology for years, the Coronavirus has caused medical doctors to turn to telehealth now more than ever in an effort to deliver “contactless” medical care to patients. According to a 2019 AMA study Click Here, telehealth was the fastest growing “place of care,” up 53% from 2016 to 2017.
Insurance denials can be frustrating for patients and physicians alike. For patients suffering from Hepatitis C, a coverage denial for Harvoni can be the difference between a complete cure and additional years of suffering.
If you or someone you love has Hepatitis C, facing a potential denial of coverage for Harvoni treatment from your insurance provider is no simple feat. (Read more about Harvoni and Harvoni-related insurance denials.) But there are ways you can improve your chances of approval and actions you can take to appeal a denial once received.
In October 2014, the Food and Drug Administration awarded approval to drug developer Gilead Sciences for a revolutionary pill: Harvoni, the first complete treatment for Hepatitis C that involves taking only one dose of one medication a day.
Tire failures occur for many reasons. A sudden, unexpected tire failure, such as tread separation, can be deadly. One reason a tire may fail is a manufacturing defect. According to the National Highway Traffic Safety Administration (NHTSA), each year an estimated 8,000 auto and truck accidents (or more) are caused by tire blowouts and other tire defects. It is very important to check your tire pressure on a regular basis and before traveling long distances.